Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many microprocessor knees have been prescribed by the NHS in England since they were introduced.
Answered by Caroline Dinenage
Since December 2016, when NHS England approved funding for the use of microprocessor controlled prosthetic knees, 350 knees have been prescribed.
In its financial planning and budget allocations, NHS England have assumed an average total cost of £14,400 for each microprocessor controlled prosthetic knee.
The circumstances in which a patient is eligible to be considered for a microprocessor knee is set out in the clinical policy on the NHS England website at the following link:
https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16061P.pdf
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the average cost of a knee prosthetic is to the public purse.
Answered by Caroline Dinenage
Since December 2016, when NHS England approved funding for the use of microprocessor controlled prosthetic knees, 350 knees have been prescribed.
In its financial planning and budget allocations, NHS England have assumed an average total cost of £14,400 for each microprocessor controlled prosthetic knee.
The circumstances in which a patient is eligible to be considered for a microprocessor knee is set out in the clinical policy on the NHS England website at the following link:
https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16061P.pdf
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, under what circumstances microprocessor knees can be prescribed to amputee patients under NHS England guidelines.
Answered by Caroline Dinenage
Since December 2016, when NHS England approved funding for the use of microprocessor controlled prosthetic knees, 350 knees have been prescribed.
In its financial planning and budget allocations, NHS England have assumed an average total cost of £14,400 for each microprocessor controlled prosthetic knee.
The circumstances in which a patient is eligible to be considered for a microprocessor knee is set out in the clinical policy on the NHS England website at the following link:
https://www.england.nhs.uk/wp-content/uploads/2016/12/clin-comm-pol-16061P.pdf
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what his Department's policy is on the administration of Kuvan to women with Phenylketonuria throughout their pregnancy.
Answered by Steve Brine
NHS England has a published policy on access to “Kuvan” (drug name Sapropterin) for phenylketonuria during pregnancy. Further information is available at:
https://www.england.nhs.uk/wp-content/uploads/2013/04/e12-p-a.pdf
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps he has taken to make Brineura (cerliponase alfa) accessible for sufferers of Batten's disease.
Answered by Steve Brine
Brineura (Cerliponase alfa) for treating Batten’s disease (neuronal ceroid lipofuscinosis type 2) was referred to the National Institute for Health and Care Excellence (NICE) for appraisal on 1 March 2017 under the highly specialised technologies programme. NICE is developing guidance which is currently scheduled for publication in June 2018.
NICE develops authoritative, evidence-based guidance on best practice for the National Health Service. NICE operates with a high degree of independence from Government and is responsible for the recommendations that it makes to the NHS. Its guidance is based on a thorough assessment of the available evidence and is developed through engagement with stakeholders.
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what recent discussions his Department has had with clinicians and patient groups on improving the implementations of bisphosphonates for the prevention of secondary breast cancer.
Answered by Steve Brine
The National Institute for Health and Care Excellence (NICE) is currently updating its guidelines on the diagnosis and management of early and locally advanced breast cancer. The use of adjuvant bisphosphonates has been identified as one of the key areas that will be covered in the update which is scheduled for publication in July 2018. In the meantime, NICE will shortly be publishing an evidence summary on the use of adjuvant bisphosphonates in early breast cancer. NHS England expects clinical commissioning groups to take account of NICE guidelines and local population needs when making commissioning decisions.
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what recent progress has been made on improving the consistency of implementation of bisphosphonates for the prevention of secondary breast cancer.
Answered by Steve Brine
The National Institute for Health and Care Excellence (NICE) is currently updating its guidelines on the diagnosis and management of early and locally advanced breast cancer. The use of adjuvant bisphosphonates has been identified as one of the key areas that will be covered in the update which is scheduled for publication in July 2018. In the meantime, NICE will shortly be publishing an evidence summary on the use of adjuvant bisphosphonates in early breast cancer. NHS England expects clinical commissioning groups to take account of NICE guidelines and local population needs when making commissioning decisions.
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment he has made of the adequacy of mental health support available for people with Parkinson's disease.
Answered by Baroness Blackwood of North Oxford
NHS England has initiated a Neurology Advisory Group, with the purpose of seeking alignment between programmes in NHS England, the other health Arm’s Length Bodies and system partners, including the Chief Executive of Parkinson’s UK, relevant to people with neurological conditions. The group has acknowledged that data from the NHS GP survey has consistently indicated that people with Neurological Conditions have the highest levels of anxiety and depression. This is an important issue and we are working with the Neurological Alliance who are due to publish a report on Mental Health and Neurological conditions in early summer. The Neurology Advisory Group will ensure that there is system alignment and a national approach to any recommendations, which will be of benefit to patients.
As set out in Implementing the Five Year Forward View for Mental Health the expansion of Improving Access to Psychological Therapies services will focus on people with long term conditions or medically unexplained symptoms. New psychological therapy provision will see physical and mental health care provision co-located. Therapy will be integrated into existing medical pathways and services – either primary care, or secondary care services including Neurology.
The report can be viewed here:
https://www.england.nhs.uk/mental-health/taskforce/imp/
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what barriers to accessing mental health services his Department has identified for people with Parkinson's disease.
Answered by Baroness Blackwood of North Oxford
NHS England has initiated a Neurology Advisory Group, with the purpose of seeking alignment between programmes in NHS England, the other health Arm’s Length Bodies and system partners, including the Chief Executive of Parkinson’s UK, relevant to people with neurological conditions. The group has acknowledged that data from the NHS GP survey has consistently indicated that people with Neurological Conditions have the highest levels of anxiety and depression. This is an important issue and we are working with the Neurological Alliance who are due to publish a report on Mental Health and Neurological conditions in early summer. The Neurology Advisory Group will ensure that there is system alignment and a national approach to any recommendations, which will be of benefit to patients.
As set out in Implementing the Five Year Forward View for Mental Health the expansion of Improving Access to Psychological Therapies services will focus on people with long term conditions or medically unexplained symptoms. New psychological therapy provision will see physical and mental health care provision co-located. Therapy will be integrated into existing medical pathways and services – either primary care, or secondary care services including Neurology.
The report can be viewed here:
https://www.england.nhs.uk/mental-health/taskforce/imp/
Asked by: Nick Thomas-Symonds (Labour - Torfaen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many people with Parkinson's disease are on a waiting list to access mental health services.
Answered by Baroness Blackwood of North Oxford
The information requested is not held.